10-QPeriod: Q3 FY2025

Guardant Health, Inc. Quarterly Report for Q3 Ended Sep 30, 2025

Filed October 29, 2025For Securities:GH

Summary

Guardant Health, Inc. reported a significant increase in revenue for the third quarter and first nine months of 2025, driven by strong performance in its Oncology and Biopharma segments. Total revenue grew by 39% year-over-year for the quarter to $265.2 million and by 30% for the nine-month period to $700.8 million. Despite revenue growth, the company continues to incur net losses, reporting a net loss of $92.7 million for the third quarter and $287.8 million for the nine months ended September 30, 2025. The company's significant investments in research and development, coupled with increased sales and marketing expenses to support product launches like Shield, contribute to these ongoing losses. However, the company maintains a healthy liquidity position with $689.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025, suggesting sufficient runway for operations.

Financial Highlights

55 data points
Beta

Revenue

$265.20M

64.7% Gross Margin

Net Income

-$92.72M

-35.0% Net Margin

EPS (Diluted)

$-0.74

Total Assets

$1.28B

Cash & Equivalents

$580.01M

Free Cash Flow

-$45.76M

Financial Statements
Beta
Revenue$265.20M
Cost of Revenue$93.59M
Gross Profit$171.61M
R&D Expenses$89.96M
Operating Expenses$364.19M
Operating Income-$98.99M
Interest Expense$943K
Net Income-$92.72M
EPS (Basic)$-0.74
EPS (Diluted)$-0.74
Shares Outstanding (Basic)124.81M
Shares Outstanding (Diluted)124.81M

Key Highlights

  • 1Total revenue increased by 39% year-over-year to $265.2 million for the three months ended September 30, 2025.
  • 2Oncology revenue grew 31% year-over-year to $184.4 million for the quarter, driven by increased test volume and improved reimbursement.
  • 3Screening revenue saw a substantial increase, reaching $24.1 million in Q3 2025, up from $1.0 million in Q3 2024, reflecting the commercial ramp-up of the Shield test.
  • 4The company's net loss for the quarter was $92.7 million, a slight improvement from $107.8 million in the prior year's quarter, indicating progress in managing expenses relative to revenue growth.
  • 5Sales and marketing expenses increased significantly by 30% to $127.4 million in Q3 2025, driven by commercial team expansion and marketing efforts for new product launches.
  • 6Cash, cash equivalents, and restricted cash stood at $689.5 million as of September 30, 2025, providing ample liquidity.
  • 7The company successfully managed its debt, completing a note exchange transaction that reduced the principal amount of its 2027 Notes and recognized a gain on extinguishment.

Frequently Asked Questions

Guardant Health reported a substantial 39% increase in total revenue for the third quarter ended September 30, 2025, reaching $265.2 million, up from $191.5 million in the same period last year. This growth was primarily fueled by a 31% increase in Oncology revenue and a significant surge in Screening revenue, highlighting the successful market introduction and adoption of its Shield test.

The company continues to invest heavily in research and development to drive innovation and expand its product pipeline, alongside increased sales and marketing expenses to support new product launches and market penetration. These strategic investments, while crucial for long-term growth, contribute to ongoing operating expenses and result in net losses. For the third quarter of 2025, the net loss was $92.7 million, a slight improvement from the prior year's $107.8 million.

Guardant Health maintains a strong liquidity position, with $689.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025. Management believes this is sufficient to meet anticipated cash requirements for more than 12 months, indicating a stable financial runway for ongoing operations and strategic initiatives.

The company is involved in several legal proceedings, including intellectual property disputes and false advertising claims. Notably, there was a jury verdict against the company in an intellectual property suit resulting in an $83.4 million liability recorded in Q4 2023, which is being contested. In a false advertising case against Natera, the company was awarded $287.0 million in damages. These ongoing legal matters introduce uncertainty and potential financial risks that investors should monitor.